Drug Information
| General Information | ||||||
|---|---|---|---|---|---|---|
| Drug ID |
DR00006
|
|||||
| Drug Name |
Moexipril
|
|||||
| Synonyms |
(3S)-2-(N-{(1S)-1-[(ethyloxy)carbonyl]-3-phenylpropyl}-L-alanyl)-6,7-bis(methyloxy)-1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid; (3S)-2-[(2S)-2-[[(2S)-1-ethoxy-1-oxo-4-phenylbutan-2-yl]amino]propanoyl]-6,7-dimethoxy-3,4-dihydro-1H-isoquinoline-3-carboxylic acid; Moexipril (INN); Moexipril [INN:BAN]; Moexiprilum; Moexiprilum [INN-Latin]; Perdix (TN); Uniretic; Univasc (TN)
|
|||||
| Drug Type |
Small molecular drug
|
|||||
| Indication | High blood pressure [ICD11:BA00] | Approved | [1] | |||
| Therapeutic Class |
Antihypertensive Agents
|
|||||
| Structure |
|
 |
||||
| 3D MOL | 2D MOL | |||||
| Formula |
C27H34N2O7
|
|||||
| Canonical SMILES |
CCOC(=O)C(CCC1=CC=CC=C1)NC(C)C(=O)N2CC3=CC(=C(C=C3CC2C(=O)O)OC)OC
|
|||||
| InChI |
InChI=1S/C27H34N2O7/c1-5-36-27(33)21(12-11-18-9-7-6-8-10-18)28-17(2)25(30)29-16-20-15-24(35-4)23(34-3)14-19(20)13-22(29)26(31)32/h6-10,14-15,17,21-22,28H,5,11-13,16H2,1-4H3,(H,31,32)/t17-,21-,22-/m0/s1
|
|||||
| InChIKey |
UWWDHYUMIORJTA-HSQYWUDLSA-N
|
|||||
| CAS Number |
CAS 103775-10-6
|
|||||
| Pharmaceutical Properties | Molecular Weight | 498.6 | Topological Polar Surface Area | 114 | ||
| Heavy Atom Count | 36 | Rotatable Bond Count | 12 | |||
| Hydrogen Bond Donor Count | 2 | Hydrogen Bond Acceptor Count | 8 | |||
| XLogP |
1.2
|
|||||
| PubChem CID | ||||||
| PubChem SID |
10224695
,103339306
,103831006
,103984203
,104404350
,117576966
,126683035
,129432080
,134222210
,134337877
,135049415
,135153605
,137003828
,141323944
,143493279
,14884255
,14933223
,151982736
,152164600
,152238590
,160964036
,162178212
,164786738
,172914179
,175266162
,178103185
,179149500
,184545955
,223440353
,223653409
,224369399
,226420555
,252390154
,44422239
,46508441
,48416289
,50077632
,51009191
,7980014
,85789110
,93166165
,96024913
,9906
|
|||||
| ChEBI ID |
ChEBI:6960
|
|||||
| TTD Drug ID | ||||||
| DT(s) Transporting This Drug | PEPT1 | Transporter Info | Peptide transporter 1 | Substrate | [2] | |
| PEPT2 | Transporter Info | Peptide transporter 2 | Substrate | [2] | ||
| References | ||||||
| 1 | Moexipril was approved by FDA. The official website of the U.S. Food and Drug Administration. (2019) | |||||
| 2 | Transport of angiotensin-converting enzyme inhibitors by H+/peptide transporters revisited. J Pharmacol Exp Ther. 2008 Nov;327(2):432-41. | |||||
If you find any error in data or bug in web service, please kindly report it to Dr. Li and Dr. Fu.